MIRA-1, a p53mut reactivator, is active on Temozolomide-resistant glioblastoma in vitro
*This study was supported in part by the “GlioTreat” grant from CGO/Région Pays de la Loire (N°2020_01246—R20060NN).
Authors
- Catherine Gratas (ORCID: https://orcid.org/0000-0002-9155-6906)
- François M. Vallette (ORCID: https://orcid.org/0000-0002-3296-8572)
- Lisa Oliver (ORCID: https://orcid.org/0000-0002-5588-7564)
- François Paris (ORCID: https://orcid.org/0000-0002-0176-7348)
- Juan Perdomo
Institutions
- Universidad de Las Palmas de Gran Canaria (ES)
- Inserm (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Molecular Biomedicine
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1186/s43556-025-00335-x
- Primary Topic
- Signaling Pathways in Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Centre Hospitalier Universitaire de Nantes
- Conseil Régional des Pays de la Loire
- Erasmus+